BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1450060)

  • 1. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'.
    Rodríguez J; Cabanillas F; McLaughlin P; Swan F; Rodríguez M; Hagemeister F; Romaguera J
    Ann Oncol; 1992 Nov; 3(9):711-7. PubMed ID: 1450060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
    Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
    Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas.
    Simon R; Durrleman S; Hoppe RT; Bonadonna G; Bloomfield CD; Rudders RA; Cheson BD; Berard CW
    Ann Intern Med; 1988 Dec; 109(12):939-45. PubMed ID: 3057985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors in low-grade lymphoma].
    Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
    Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in intermediate and high-grade non-Hodgkin's lymphomas of adults: a need for a new staging system.
    el-Ghamrawy KA; Zawam HZ; Abdel-Azim H; Haggag M
    Anticancer Drugs; 1991 Aug; 2(4):383-8. PubMed ID: 1797195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
    Cabanillas F; Rodriguez-Diaz Pavón J; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera JE; Dong K; Moon T
    Ann Oncol; 1998 May; 9(5):511-8. PubMed ID: 9653492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.
    Velasquez WS; Jagannath S; Tucker SL; Fuller LM; North LB; Redman JR; Swan F; Hagemeister FB; McLaughlin P; Cabanillas F
    Blood; 1989 Aug; 74(2):551-7. PubMed ID: 2752132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity.
    Yamanaka N; Harabuchi Y; Kataura A
    Cancer; 1992 Nov; 70(9):2342-9. PubMed ID: 1394063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage.
    Vonderheid EC; Diamond LW; van Vloten WA; Scheffer E; Meijer CJ; Cashell AW; Hardman JM; Lai SM; Hermans J; Matthews MJ
    Cancer; 1994 Jan; 73(1):207-18. PubMed ID: 8275427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in the management of lymphomas at M.D. Anderson Cancer Center.
    Cabanillas F; Rodríguez MA; Swan F
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):28-32; discussion 32-3. PubMed ID: 2259921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
    Simon R; Durrleman S; Hoppe RT; Bonadonna G; Bloomfield CD; Rudders RA; Cheson BD; Berard CW
    Med Pediatr Oncol; 1990; 18(2):89-96. PubMed ID: 2406556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
    Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
    Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The non-Hodgkin's lymphomas: pathology, staging, treatment.
    Hoppe RT
    Curr Probl Cancer; 1987; 11(6):363-447. PubMed ID: 3125008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
    Touroutoglou N; Dimopoulos MA; Younes A; Hess M; Pugh W; Cox J; Cabanillas F; Sarris AH
    J Clin Oncol; 1995 Jun; 13(6):1361-7. PubMed ID: 7751880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
    Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
    Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNM staging system may be superior to Lugano and Ann Arbor systems in predicting the overall survival of patients with primary gastrointestinal lymphoma.
    Chang S; Shi X; Xu Z; Liu Q
    J BUON; 2015; 20(3):812-9. PubMed ID: 26214635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
    Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
    Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.